Zoeken
Urologie

Klinische studies dienst urologie

Bekijk het overzicht van de studies die op dit moment aangeboden kunnen worden aan patiënten met urologische tumoren en andere urologische problemen.
Op deze pagina

Blaas- en urinewegentumoren

TAR-210 MoonRISE-3

A phase 3, randomized study evaluating the efficacy and safety of TAR-210 Erdafitinib intravesical delivery system vs. intravesical chemotherapy in participants with High-risk Non-muscle-invasive Bladder Cancer with susceptible FGFR alterations who received intravesical BCG

  • Inclusion criteria: Papillary-only HR-NMIBC (defined as HG Ta or any T1, no CIS), susceptible FGFR mutation (urine of tissue), recurrence within 12 months after BCG
  • Exclusion criteria: Presence of CIS, UC or histological variant at any site outside of the urinary bladder, N+ and/or M+ per BICR of CT/MR Urography
  • Investigator: prof. dr. Ben Van Cleynenbreugel
  • Sub-investigator (Urology): dr. Carl Van Haute
  • More information: NCT06919965

SINCERE Registry

Effect of a single instillation of Mitomycin C on the intravesical recurrence rate after ureteroscopy for Upper Tract Urothelial Carcinoma: A prospective, multicenter registry study. 

  • Inclusion criteria: All patients ≥ 18 years old with clinically non-metastatic UTUC planned for URS, either as a diagnostic or as treatment, followed by a SI-MMC (or any equivalent) are eligible for this study.
  • Local site Principal Investigator: dr. Carl Van Haute
  • More information: NCT05731622

Niertumoren

Er zijn momenteel geen studies beschikbaar.

Penistumoren

Er zijn momenteel geen studies beschikbaar.

Prostaattumoren

MEVPRO-3

A phase 3, randomized, double-blind, placebo-controlled study of Mevrometostat (EZH2 inhibitor) with enzalutamide in metastatic castration-sensitive prostate cancer

  • Inclusion criteria: mCSPC (adenocarcinoma), de novo or recurrent; Surgical or medical castration; Must be treatment naive at the mCSPC stage (max 3m ADT prior to study treatment en Bicalutamide (Casodex)).
  • Exclusion criteria: RP or definitive RT to the primary prostate tumor for mCSPC with curative intent is not permitted; patient may  have received 1 course of palliative radiation or surgery for symptomatic control secondary to prostate  cancer, which should be completed at least 2 weeks prior to randomization; No prior EZH2 inhibitor.
  • Investigator: prof. dr. Steven Joniau
  • More information: NCT07028853

DE-ESCALATE

Intermittent Androgen Deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial

Testistumoren

Er zijn momenteel geen studies beschikbaar.

Urinaire incontinentie

AURA-4X

Personalised adaptive pudendal neuromodulation for mixed urinary incontinence and extended indications using an implanted system.

  • Inclusion criteria: Women (≥ 22 years) with urinary incontinence, both urge and stress UI (mixed incontinence)
  • Exclusion criteria: botox injections within last 6 months, sacral neuromodulation in the past, sling within last 3 years
  • Investigator: prof. dr. Frank Van der Aa
  • Sub-investigator: dr. Marie-Elise Henckes
  • More information: NCT06885931

NEMISIS

Sacral neuromodulation as treatment for voiding dysfunction in multiple sclerosis patients.

  • Inclusion criteria: Diagnosis of Multiple Sclerosis according the McDonald criteria, stable relapsing remitting MS, EDSS 0-6, storage LUTD with Urgency Frequency or Urgency Urinary Incontinence.
  • Local site Principal Investigator: prof. dr. Frank Van der Aa
  • Sub-investigator (Urology): dr. Lisa Moris
  • More information: urologie.trial@uzleuven.be

Urineweg-infecties

MINUS Trial

Multicentric study on Infections of the Urinary tract after Stent removal

  • Inclusion criteria: Patients, 18 years of age and older who receive a ureteral stent during any endoscopic procedure will be approached to participate in the study
  • Local site Principal Investigator: dr. Carl Van Haute
  • Sub-investigator (Urology): prof. dr. Ben Van Cleynenbreugel
  • More information: NCT05329883

Zelfkatheterisatie

EVA studie

Study of Colopast catheter selection criteria at start of self-catheterisation

  • Inclusion criteria: patients with neurogenic or non-neurogenic bladder issues, justifying the implementation of intermittent self-catheterisation (ISC) to clean out the bladder, for at least 6 months
  • Local site Principal Investigator: prof. dr. Frank Van Der Aa
  • Sub-investigator: dr. Lisa Moris
  • More information: NCT05065255

Questions

For more information, please contact trial urology.

Laatste aanpassing: 10 maart 2026